



Tumor Treating Fields : Additional Mechanisms and Additional Applications

Ashwin Kumaria

Department of Neurosurgery, Queen's Medical Centre, Nottingham, UK

To the Editor,

Glioblastoma (GBM) is the commonest malignant brain tumor with an almost uniformly lethal outcome. Despite aggressive surgical and adjuvant oncological intervention, median survival is around 12–15 months^{10,14}. Although controversial, there is a trend favoring maximal safe resection in GBM surgery^{2,4,5}. Conventional oncological treatments include radiotherapy and chemotherapy¹⁰, although it is important to appreciate that there has been little improvement in the standard of care in patients with newly diagnosed GBM since the Stupp protocol was reported.

Tumor Treating Fields (TTFields) are low intensity, intermediate frequency, alternating electric fields which have been shown to significantly increase progression-free survival and overall survival in patients with primary and recurrent GBM^{6,11-13}. An interesting recent article reviews TTFields in GBM, focusing on the anti-mitotic and anti-microtubule effects²². Briefly, TTFields arrest tumor cell mitosis in interphase, prolong tumor mitotic cycles, and cause cell fragmentation and inhibit tumor cell proliferation²². The authors are hereby congratulated on an excellent, well-balanced and authoritative paper. The opinions and observations provided

here are merely additional novel mechanisms by which TTFields may contribute to an anti-glioma effect, beyond inhibiting mitosis. Accordingly, additional applications for TTFields are suggested herein.

Neuronal activity-dependent glutamatergic neurotransmission has been shown to play an essential role in the propagation of glioma^{17,18,20}. The concept of the “neurogliomal synapse” has been put forth, whereby glutamate originating from neurons acts on postsynaptic glutamatergic receptors on glioma cells to promote glioma growth and invasiveness^{16,19}. Blocking this glutamatergic signaling through anti-epileptic and anesthetic agents demonstrated anti-glioma effects¹⁶. An external electrical field may interfere with glutamatergic signaling – as has been demonstrated in patients with epilepsy¹ – and this may be another mechanism by which TTFields may exert its anti-glioma effect. Furthermore, glutamatergic signaling has been shown to promote metastasis of systemic tumors to the brain²¹. A role for TTFields in treatment of brain metastases has previously been proposed³, and it will be interesting to see if a TTFields-mediated anti-glutamate role contributes here.

The cell of origin in GBM is thought to be endogenous neural stem cells residing in periventricular niches⁷⁻⁹. Electrical

• Received : June 27, 2020 • Revised : July 21, 2020 • Accepted : August 20, 2020

• Address for reprints : **Ashwin Kumaria**

Department of Neurosurgery, Queen's Medical Centre, C-floor West Block, Derby Road, Nottingham NG7 2UH, UK

Tel : +44-1159249924, Fax : +44-1159249924, E-mail : Ashwin.Kumaria@doctors.org.uk, ORCID : <https://orcid.org/0000-0002-8145-0374>

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

fields generated as a byproduct of deep brain stimulation have been shown to significantly influence the neural stem cell niche¹⁵, potentially evoking a less gliomagenic niche. It is possible that TTFields exert a similar influence to prevent neural stem cells from promoting or contributing to glioma growth.

A potential drawback with TTFields as they stand is that anti-tumor efficacy and patient survival correlates with dose, which is the duration patients must be wearing their device^{6,12}. Furthermore, GBM is typically a deep tumor, frequently extending to the margin of the lateral ventricles. The electrical field must penetrate soft tissue, calvarium, meninges, gray and white matter before tumor is reached. Each aforementioned anatomical structure confers electrical resistance and the electrical field would be dampened as a result. Two ideas emerge from this. Firstly, children have thinner skulls and extracranial soft tissue – TTFields may be more efficacious in this patient group owing to lesser impedance. However, supratentorial malignant gliomas are less frequent in children. Secondly, there is the possibility of retaining electrodes at the time of tumor surgery for the purposes of delivering a more focused electrical field at the site of the tumor. Therefore, there may be a role for surgical neuromodulation in GBM. Advances in electrical field therapy in GBM may be extrapolated to other tumors, including tumors outside of the central nervous system.

In conclusion, additional mechanisms to explain the anti-glioma effect of TTFields are presented here. Additional applications and indications are presented including a possible role for surgical neuromodulation. Further research is warranted.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

INFORMED CONSENT

This type of study does not require informed consent.

AUTHOR CONTRIBUTIONS

Conceptualization : AK

Data curation : AK

Formal analysis : AK

Funding acquisition : AK

Methodology : AK

Project administration : AK

Visualization : AK

Writing - original draft : AK

Writing - review & editing : AK

ORCID

Ashwin Kumaria <https://orcid.org/0000-0002-8145-0374>

References

1. Badawy RA, Strigaro G, Cantello R : TMS, cortical excitability and epilepsy: the clinical impact. **Epilepsy Res** **108** : 153-161, 2014
2. D'Amico RS, Englander ZK, Canoll P, Bruce JN : Extent of resection in glioma-a review of the cutting edge. **World Neurosurg** **103** : 538-549, 2017
3. Davies AM, Weinberg U, Palti Y : Tumor treating fields: a new frontier in cancer therapy. **Ann N Y Acad Sci** **1291** : 86-95, 2013
4. Hervey-Jumper SL, Berger MS : Evidence for improving outcome through extent of resection. **Neurosurg Clin N Am** **30** : 85-93, 2019
5. Hervey-Jumper SL, Berger MS : Maximizing safe resection of low- and high-grade glioma. **J Neurooncol** **130** : 269-282, 2016
6. Kanner AA, Wong ET, Villano JL, Ram Z; EF-11 Investigators : Post hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A™ system versus best physician's choice chemotherapy. **Semin Oncol** **41(Suppl 6)** : S25-S34, 2014
7. Kusne Y, Sanai N : The SVZ and its relationship to stem cell based neuro-oncogenesis. **Adv Exp Med Biol** **853** : 23-32, 2015
8. Lee JH, Lee JE, Kahng JY, Kim SH, Park JS, Yoon SJ, et al. : Human glioblastoma arises from subventricular zone cells with low-level driver mutations. **Nature** **560** : 243-247, 2018
9. Sanai N, Alvarez-Buylla A, Berger MS : Neural stem cells and the origin of gliomas. **N Engl J Med** **353** : 811-822, 2005
10. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. **N Engl J Med** **352** : 987-996, 2005
11. Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et al. : Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a

- randomized clinical trial. **JAMA** **318** : 2306-2316, 2017
12. Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, et al. : NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. **Eur J Cancer** **48** : 2192-2202, 2012.
 13. Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, et al. : Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. **JAMA** **314** : 2535-2543, 2015
 14. Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS, et al. : Epidemiologic and molecular prognostic review of glioblastoma. **Cancer Epidemiol Biomarkers Prev** **23** : 1985-1996, 2014
 15. Toda H, Hamani C, Fawcett AP, Hutchison WD, Lozano AM : The regulation of adult rodent hippocampal neurogenesis by deep brain stimulation. **J Neurosurg** **108** : 132-138, 2008
 16. Venkataramani V, Tanev DI, Strahle C, Studier-Fischer A, Fankhauser L, Kessler T, et al. : Glutamatergic synaptic input to glioma cells drives brain tumour progression. **Nature** **573** : 532-538, 2019
 17. Venkatesh H, Monje M : Neuronal activity in ontogeny and oncology. **Trends Cancer** **3** : 89-112, 2017
 18. Venkatesh HS, Johung TB, Caretti V, Noll A, Tang Y, Nagaraja S, et al. : Neuronal activity promotes glioma growth through neuroligin-3 secretion. **Cell** **161** : 803-816, 2015
 19. Venkatesh HS, Tam LT, Woo PJ, Lennon J, Nagaraja S, Gillespie SM, et al. : Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. **Nature** **549** : 533-537, 2017
 20. Venkatesh HS, Morishita W, Geraghty AC, Silverbush D, Gillespie SM, Arzt M, et al. : Electrical and synaptic integration of glioma into neural circuits. **Nature** **573** : 539-545, 2019
 21. Zeng Q, Michael IP, Zhang P, Saghafinia S, Knott G, Jiao W, et al. : Synaptic proximity enables NMDAR signalling to promote brain metastasis. **Nature** **573** : 526-531, 2019
 22. Zhang C, Du J, Xu W, Huang H, Gao L : The value of tumor treating fields in glioblastoma. **J Korean Neurosurg Soc** **63** : 681-688, 2020